



Dedicated To Life

November 2, 2022

<b>BSE Limited</b> 1 <sup>st</sup> Floor, P J Towers, Dalal Street, <u>Mumbai-400001</u>	<b>Code: 532321</b>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, 5 <sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), <u>Mumbai-400051</u>	<b>Code: Zyduslife</b>
--	---------------------	---	------------------------

**Sub: Acquisition of further stake in AMP Energy Green Nine Private Limited**

**Ref.: 1. Disclosure under regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated September 9, 2015**

**2. Our earlier intimations dated March 16, 2022 and September 22, 2022**

Dear Sir/Madam,

In our intimation dated March 16, 2022, we informed that the Company had entered into Share Purchase, Subscription and Shareholder's Agreement ("**SPSSA**") to acquire upto 11.86% stake on a fully diluted basis in AMP Energy Green Nine Private Limited ("**AMP**"), for setting up a captive Wind Solar Hybrid power project in Gujarat.

In our intimation dated September 22, 2022, we informed that as per the terms of SPSSA, the Company would be subscribing to additional equity shares and compulsorily convertible debentures of AMP.

Now, we inform that, the Company has entered into First Amendment Agreement to the SPSSA on November 2, 2022 to acquire additional stake of 0.31% on a fully diluted basis in AMP, resulting into aggregate stake of 12.17% on a fully diluted basis in AMP.

Requisite disclosure as required under the SEBI Circular dated September 9, 2015 is enclosed as **Annexure-I**.

Please take the above information on record.

Thanking you,

Yours faithfully,

For, **Zydus Lifesciences Limited**

**Dhaval N. Soni**  
**Company Secretary**

**Encl.:** As above

**Zydus Lifesciences Limited** (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878





Dedicated To Life

### Annexure-I

Sr. No.	Particulars	Details
a)	Name of the target entity, details in brief such as size, turnover etc.;	<p><b>Name of the target entity:</b> AMP Energy Green Nine Private Limited ("<b>AMP</b>")</p> <p><b>Brief Details:</b> AMP, a wholly owned subsidiary of AMP Energy C&amp;I Private Limited ("<b>AMP C&amp;I</b>"), is a Special Purpose Vehicle formed for purpose of setting up captive Wind Solar Hybrid power project in Gujarat. Both AMP and AMP C&amp;I are subsidiaries of AMP Energy India Private Limited. AMP Energy India Private Limited is engaged in the business of developing, owning, operating and maintaining renewable energy infrastructure for supplying electrical power generated using solar energy and other sources of renewable energy to commercial, industrial and utility customers.</p> <p><b>Turnover:</b> Nil as on March 31, 2022.</p>
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	<p>Subscription of additional equity shares of Rs. 10/- each and compulsorily convertible debentures of Rs. 1,000/- each ("<b>CCDs</b>") doesn't fall within the purview of related party transactions.</p> <p>None of the promoter/promoter group has any interest in the entity.</p> <p>The said subscription by the Company will be on an arm's length basis.</p>
c)	Industry to which the entity being acquired belongs;	Generation and transmission of Wind Solar Hybrid energy and other sources of renewable energy.
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	In line with the Company's commitment to enhance the share of renewable power source in its operation and to comply with regulatory requirement for being a captive user under Electricity Laws, 2003, the Company will acquire up to 12.17% stake, in one or more tranches, on fully diluted basis in AMP throughout the term of the definitive agreements i.e., Power Purchase Agreement, SPSSA and First Amendment Agreement to SPSSA.

**Zydus Lifesciences Limited** (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878





Dedicated To Life

Sr. No.	Particulars	Details																														
e)	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable																														
f)	Indicative time-period for completion of the acquisition;	Subscription to additional equity shares and CCDs to be completed within a period of 7 days from the date of entering into First Amendment Agreement to SPSSA.																														
g)	Nature of consideration-whether cash consideration or share swap and details of the same;	Cash consideration.																														
h)	Cost of acquisition or the price at which the shares are acquired;	<p>Details of cost of subscription to additional equity shares and CCDs by the Company are provided in below table:</p> <table border="1"> <thead> <tr> <th>Sr. No.</th> <th>Equity Shares / CCDs</th> <th>No. of Shares / CCDs</th> <th>Face Value (Rs.)</th> <th>Amount (Rs. in lacs)</th> </tr> </thead> <tbody> <tr> <td>1.</td> <td>Subscription to additional equity shares</td> <td>38,280</td> <td>10</td> <td>3.83</td> </tr> <tr> <td colspan="2"><b>Equity Shares (A)</b></td> <td><b>38,280</b></td> <td></td> <td><b>3.83</b></td> </tr> <tr> <td>2.</td> <td>Subscription to additional CCDs</td> <td>3,446</td> <td>1,000</td> <td>34.46</td> </tr> <tr> <td colspan="2"><b>CCDs (B)</b></td> <td><b>3,446</b></td> <td></td> <td><b>34.46</b></td> </tr> <tr> <td colspan="2"><b>Total (A + B)</b></td> <td></td> <td></td> <td><b>38.29</b></td> </tr> </tbody> </table> <p>Total amount of investment by the Company after taking into consideration the earlier investments made in March, 2022, September, 2022 and the subscription to additional equity shares and CCDs is provided at the end of this disclosure.</p>	Sr. No.	Equity Shares / CCDs	No. of Shares / CCDs	Face Value (Rs.)	Amount (Rs. in lacs)	1.	Subscription to additional equity shares	38,280	10	3.83	<b>Equity Shares (A)</b>		<b>38,280</b>		<b>3.83</b>	2.	Subscription to additional CCDs	3,446	1,000	34.46	<b>CCDs (B)</b>		<b>3,446</b>		<b>34.46</b>	<b>Total (A + B)</b>				<b>38.29</b>
Sr. No.	Equity Shares / CCDs	No. of Shares / CCDs	Face Value (Rs.)	Amount (Rs. in lacs)																												
1.	Subscription to additional equity shares	38,280	10	3.83																												
<b>Equity Shares (A)</b>		<b>38,280</b>		<b>3.83</b>																												
2.	Subscription to additional CCDs	3,446	1,000	34.46																												
<b>CCDs (B)</b>		<b>3,446</b>		<b>34.46</b>																												
<b>Total (A + B)</b>				<b>38.29</b>																												

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
 website : www.zyduslife.com | CIN : L24230GJ1995PLC025878





Dedicated To Life

Sr. No.	Particulars	Details												
i)	Percentage of shareholding / control acquired and / or number of shares acquired;	Considering the details provided in the table in 'h)' above, the details of stake in AMP on a fully diluted basis, are provided in below table: <table border="1"><thead><tr><th>Sr. No.</th><th>Name of the Company</th><th>% stake in AMP</th></tr></thead><tbody><tr><td>1.</td><td>Zydus Lifesciences Limited</td><td>12.17</td></tr><tr><td>2.</td><td>German Remedies Pharmaceuticals Private Limited</td><td>0.43</td></tr><tr><td colspan="2"><b>Total</b></td><td><b>12.60</b></td></tr></tbody></table>	Sr. No.	Name of the Company	% stake in AMP	1.	Zydus Lifesciences Limited	12.17	2.	German Remedies Pharmaceuticals Private Limited	0.43	<b>Total</b>		<b>12.60</b>
Sr. No.	Name of the Company	% stake in AMP												
1.	Zydus Lifesciences Limited	12.17												
2.	German Remedies Pharmaceuticals Private Limited	0.43												
<b>Total</b>		<b>12.60</b>												
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief);	AMP was incorporated on September 15, 2020 India and is engaged in business of generating, producing, accumulating, storing, improving, buying, selling, reselling, transmitting, distributing, and supplying electrical power generated using solar energy and other sources of renewable energy and developing infrastructure projects based on solar energy.  <b>History of last 3 years turnover: NIL</b>  <b>Country: India</b>												

**Zydus Lifesciences Limited** (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878





Dedicated To Life

**Total amount of investment by the Company, after taking into consideration the earlier investment / subscription made in March, 2022, September, 2022 and the subscription to additional equity shares and CCDs is provided in below table:**

Sr. No.	Date of investment	Company	Particulars of investment	No. of Equity Shares	Aggregate amount of investment in Equity Shares (Rs. In lacs)	No. of CCDs	Aggregate amount of investment in CCDs (Rs. In lacs)	Aggregate amount of investment (Equity Shares + CCDs) (Rs. In lacs)
1	March 28, 2022 (earlier investment and subscription)	Zydus Lifesciences Limited	Purchase from AMP C&I	3,18,519	31.85	--	--	<b>31.85</b>
2			Subscription	--	--	32,680	326.80	<b>326.80</b>
3		German Remedies Pharmaceuticals Private Limited	Purchase from AMP C&I	11,542	1.15	--	--	<b>1.15</b>
4			Subscription	--	--	1,185	11.85	<b>11.85</b>
5	September 22, 2022 (additional subscription)	Zydus Lifesciences Limited	Subscription	10,02,141	100.21	86,180	861.80	<b>962.01</b>
6		German Remedies Pharmaceuticals Private Limited	Subscription	36,308	3.63	3,122	31.22	<b>34.85</b>
7	November 2, 2022 (additional subscription)	Zydus Lifesciences Limited	Subscription	38,280	3.83	3,446	34.46	<b>38.29</b>
8		German Remedies Pharmaceuticals Private Limited	--	--	--	--	--	<b>--</b>
<b>Total (A)</b>				<b>14,06,790</b>	<b>140.67</b>	<b>1,26,613</b>	<b>1,266.13</b>	<b>1,406.80</b>
<b>Company wise bifurcation of Total (A) is as under:</b>								
<b>Zydus Lifesciences Limited</b>				<b>13,58,940</b>	<b>135.89</b>	<b>1,22,306</b>	<b>1,223.06</b>	<b>1,358.95</b>
<b>German Remedies Pharmaceuticals Private Limited</b>				<b>47,850</b>	<b>4.78</b>	<b>4,307</b>	<b>43.07</b>	<b>47.85</b>

**Zydus Lifesciences Limited** (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878

